Enrollment Completed In The Feasibility Phase Of The FORESEE Clinical Trial With Biocept's CNSide Assay To Evaluate Patients With Leptomeningeal Metastases
Portfolio Pulse from Benzinga Newsdesk
Biocept, Inc. (NASDAQ:BIOC) has completed the enrollment of 40 subjects in the feasibility phase of its FORESEE clinical trial, which is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of leptomeningeal metastases (LM). The company aims to establish CNSide as a standard of care under the National Comprehensive Cancer Network guidelines. The trial is designed to measure the impact of CNSide on physicians' clinical decisions. Biocept expects to have results from the feasibility phase of the trial in the first half of 2024.
September 21, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biocept's completion of enrollment for the feasibility phase of its FORESEE clinical trial could potentially boost investor confidence in the company's ability to innovate and deliver on its pipeline. However, the results of the trial, expected in the first half of 2024, will be a more significant determinant of the stock's performance.
The completion of enrollment for the feasibility phase of the FORESEE trial is a positive development for Biocept, indicating progress in its clinical pipeline. However, the impact on the stock price in the short term may be limited, as the results of the trial, which are expected in the first half of 2024, will be a more significant determinant of the stock's performance. The trial's success could potentially lead to the adoption of CNSide as a standard of care, which would likely have a positive impact on Biocept's revenues and profitability.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100